![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CYBRD1 |
Gene summary for CYBRD1 |
![]() |
Gene information | Species | Human | Gene symbol | CYBRD1 | Gene ID | 79901 |
Gene name | cytochrome b reductase 1 | |
Gene Alias | CYB561A2 | |
Cytomap | 2q31.1 | |
Gene Type | protein-coding | GO ID | GO:0000041 | UniProtAcc | Q53TN4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79901 | CYBRD1 | GSM4909299 | Human | Breast | IDC | 8.34e-08 | 3.28e-01 | 0.035 |
79901 | CYBRD1 | GSM4909300 | Human | Breast | IDC | 1.61e-02 | 2.94e-01 | 0.0334 |
79901 | CYBRD1 | GSM4909307 | Human | Breast | IDC | 9.14e-09 | 3.57e-01 | 0.1569 |
79901 | CYBRD1 | GSM4909308 | Human | Breast | IDC | 3.57e-19 | 4.73e-01 | 0.158 |
79901 | CYBRD1 | GSM4909311 | Human | Breast | IDC | 8.80e-04 | -6.18e-03 | 0.1534 |
79901 | CYBRD1 | GSM4909312 | Human | Breast | IDC | 7.26e-03 | 2.37e-01 | 0.1552 |
79901 | CYBRD1 | GSM4909319 | Human | Breast | IDC | 6.48e-05 | -7.86e-02 | 0.1563 |
79901 | CYBRD1 | M5 | Human | Breast | IDC | 1.76e-06 | 7.07e-01 | 0.1598 |
79901 | CYBRD1 | DCIS2 | Human | Breast | DCIS | 7.72e-45 | 2.20e-01 | 0.0085 |
79901 | CYBRD1 | LZE5T | Human | Esophagus | ESCC | 2.70e-02 | 5.14e-02 | 0.0514 |
79901 | CYBRD1 | LZE24T | Human | Esophagus | ESCC | 4.64e-05 | -2.99e-04 | 0.0596 |
79901 | CYBRD1 | P2T-E | Human | Esophagus | ESCC | 5.61e-10 | -4.04e-02 | 0.1177 |
79901 | CYBRD1 | P4T-E | Human | Esophagus | ESCC | 1.61e-12 | 1.59e-01 | 0.1323 |
79901 | CYBRD1 | P8T-E | Human | Esophagus | ESCC | 6.24e-21 | 4.05e-01 | 0.0889 |
79901 | CYBRD1 | P9T-E | Human | Esophagus | ESCC | 1.19e-08 | 9.64e-02 | 0.1131 |
79901 | CYBRD1 | P10T-E | Human | Esophagus | ESCC | 4.94e-08 | 2.36e-01 | 0.116 |
79901 | CYBRD1 | P11T-E | Human | Esophagus | ESCC | 6.88e-05 | 7.79e-02 | 0.1426 |
79901 | CYBRD1 | P12T-E | Human | Esophagus | ESCC | 7.29e-15 | 2.30e-01 | 0.1122 |
79901 | CYBRD1 | P16T-E | Human | Esophagus | ESCC | 8.41e-16 | 1.07e-01 | 0.1153 |
79901 | CYBRD1 | P19T-E | Human | Esophagus | ESCC | 1.03e-04 | 1.52e-01 | 0.1662 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001003830 | Thyroid | HT | response to metal ion | 50/1272 | 373/18723 | 3.12e-06 | 1.08e-04 | 50 |
GO:004691616 | Thyroid | HT | cellular transition metal ion homeostasis | 16/1272 | 115/18723 | 4.78e-03 | 3.29e-02 | 16 |
GO:005507619 | Thyroid | HT | transition metal ion homeostasis | 18/1272 | 138/18723 | 5.75e-03 | 3.72e-02 | 18 |
GO:0010038112 | Thyroid | PTC | response to metal ion | 157/5968 | 373/18723 | 1.80e-05 | 1.86e-04 | 157 |
GO:0055076110 | Thyroid | PTC | transition metal ion homeostasis | 62/5968 | 138/18723 | 8.66e-04 | 5.30e-03 | 62 |
GO:005507210 | Thyroid | PTC | iron ion homeostasis | 39/5968 | 85/18723 | 4.71e-03 | 2.21e-02 | 39 |
GO:004691617 | Thyroid | goiters | cellular transition metal ion homeostasis | 10/497 | 115/18723 | 9.82e-04 | 2.03e-02 | 10 |
GO:005507625 | Thyroid | goiters | transition metal ion homeostasis | 11/497 | 138/18723 | 1.15e-03 | 2.30e-02 | 11 |
GO:0010038210 | Thyroid | ATC | response to metal ion | 165/6293 | 373/18723 | 1.07e-05 | 1.05e-04 | 165 |
GO:005507632 | Thyroid | ATC | transition metal ion homeostasis | 66/6293 | 138/18723 | 3.64e-04 | 2.25e-03 | 66 |
GO:005507214 | Thyroid | ATC | iron ion homeostasis | 41/6293 | 85/18723 | 3.62e-03 | 1.58e-02 | 41 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0497814 | Prostate | BPH | Mineral absorption | 20/1718 | 60/8465 | 1.22e-02 | 3.61e-02 | 2.23e-02 | 20 |
hsa0497815 | Prostate | BPH | Mineral absorption | 20/1718 | 60/8465 | 1.22e-02 | 3.61e-02 | 2.23e-02 | 20 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CYBRD1 | SNV | Missense_Mutation | c.787N>C | p.Glu263Gln | p.E263Q | Q53TN4 | protein_coding | deleterious(0.03) | benign(0.307) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
CYBRD1 | SNV | Missense_Mutation | c.827C>T | p.Ala276Val | p.A276V | Q53TN4 | protein_coding | tolerated_low_confidence(0.15) | benign(0.01) | TCGA-AO-A1KR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
CYBRD1 | SNV | Missense_Mutation | novel | c.676C>T | p.Arg226Cys | p.R226C | Q53TN4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CYBRD1 | SNV | Missense_Mutation | c.21N>T | p.Trp7Cys | p.W7C | Q53TN4 | protein_coding | tolerated(0.18) | benign(0) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CYBRD1 | SNV | Missense_Mutation | c.530G>A | p.Gly177Glu | p.G177E | Q53TN4 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CYBRD1 | SNV | Missense_Mutation | novel | c.256N>A | p.His86Asn | p.H86N | Q53TN4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CYBRD1 | SNV | Missense_Mutation | novel | c.225N>T | p.Trp75Cys | p.W75C | Q53TN4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CYBRD1 | SNV | Missense_Mutation | c.474N>G | p.Ile158Met | p.I158M | Q53TN4 | protein_coding | tolerated(0.05) | benign(0.079) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
CYBRD1 | SNV | Missense_Mutation | c.549N>G | p.Ile183Met | p.I183M | Q53TN4 | protein_coding | deleterious(0.03) | possibly_damaging(0.718) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
CYBRD1 | SNV | Missense_Mutation | novel | c.562G>T | p.Asp188Tyr | p.D188Y | Q53TN4 | protein_coding | deleterious(0.02) | benign(0) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |